HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis.

AbstractOBJECTIVE:
We studied the effects of intravenous immunoglobulin (IVIG) treatment on clinical symptoms and regulatory T (Treg) cell frequency in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
METHODS:
Twenty-two EGPA patients with severe mononeuritis multiplex or cardiac dysfunction received IVIG therapy combined with conventional therapy (corticosteroid, immunosuppressants, or both). As a control, 24 EGPA patients without severe vasculitic symptoms were treated with conventional therapy. Before, during, and after treatment, we determined percentages of Treg cells and other relevant cells in patients' peripheral blood.
RESULTS:
The frequency of CD25+ among CD4+ T cells was lower at onset in the study group than in controls but increased significantly after IVIG treatment, relative to controls. The frequency of CD25+ among CD4+ T cells correlated with the frequency of FOXP3+ among CD4+ T cells and interleukin 10 produced by CD25+CD4+ T cells.
CONCLUSION:
The increase in Treg cells seen with the combination of IVIG and conventional therapy may promote remission in EGPA.
AuthorsNaomi Tsurikisawa, Hiroshi Saito, Chiyako Oshikata, Takahiro Tsuburai, Kazuo Akiyama
JournalThe Journal of rheumatology (J Rheumatol) Vol. 39 Issue 5 Pg. 1019-25 (May 2012) ISSN: 0315-162X [Print] Canada
PMID22467925 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Immunoglobulins, Intravenous
  • Immunologic Factors
Topics
  • Adult
  • Aged
  • Churg-Strauss Syndrome (drug therapy, immunology)
  • Dose-Response Relationship, Immunologic
  • Eosinophilic Granuloma (drug therapy, immunology)
  • Female
  • Humans
  • Immunoglobulins, Intravenous (administration & dosage)
  • Immunologic Factors (administration & dosage)
  • Male
  • Middle Aged
  • Severity of Illness Index
  • T-Lymphocytes, Regulatory (immunology, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: